Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH): a systematic analysis of expert opinion.
Lowe FC, Batista J, Berges R, Chartier-Kastler E, Conti G, Desgrandchamps F, Dreikorn K, O'Leary M, Perez M, Speakman M, Trachtenberg J, Tubaro A, Meesen B, Smets L, Stoevelaar H. Lowe FC, et al. Among authors: speakman m. Prostate Cancer Prostatic Dis. 2005;8(3):206-9. doi: 10.1038/sj.pcan.4500806. Prostate Cancer Prostatic Dis. 2005. PMID: 15953934
Integrating risk profiles for disease progression in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia: a combined analysis of external evidence and clinical expertise.
Speakman M, Batista J, Berges R, Chartier-Kastler E, Conti G, Desgrandchamps F, Dreikorn K, Lowe F, O'Leary M, Perez M, Trachtenberg J, Tubaro A, Meesen B, Smets L, Stoevelaar H. Speakman M, et al. Prostate Cancer Prostatic Dis. 2005;8(4):369-74. doi: 10.1038/sj.pcan.4500827. Prostate Cancer Prostatic Dis. 2005. PMID: 16130013
Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group.
Schulman CC, Cortvriend J, Jonas U, Lock TM, Vaage S, Speakman MJ. Schulman CC, et al. Among authors: speakman mj. Eur Urol. 1999 Dec;36(6):609-20. doi: 10.1159/000020056. Eur Urol. 1999. PMID: 10559616 Clinical Trial.
Should we really consider Gleason 6 prostate cancer?
Nickel JC, Speakman M. Nickel JC, et al. Among authors: speakman m. BJU Int. 2012 Mar;109(5):645-6. doi: 10.1111/j.1464-410X.2011.10854.x. Epub 2011 Dec 22. BJU Int. 2012. PMID: 22193242 No abstract available.
Reasons to consider prostatic artery embolization.
Abt D, Schmid HP, Speakman MJ. Abt D, et al. Among authors: speakman mj. World J Urol. 2021 Jul;39(7):2301-2306. doi: 10.1007/s00345-021-03601-z. Epub 2021 Feb 10. World J Urol. 2021. PMID: 33569641 Review.
112 results